v2.4.0.6
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
 9 Months Ended 12 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Dec. 31, 2010
Dec. 31, 2009
Cash flow from operating activities:        
Net loss $ (6,927,652) $ (4,787,637) $ (7,040,767) $ (2,439,851)
Adjustments to reconcile net loss to net cash used in operating activities:        
Amortization of contingent note payable and note discounts 400,498 258,449 468,157 44,064
Amortization of debt premiums (284,061)      
Depreciation and patent amortization 47,035 160,083 214,051 52,694
Patent impairment charge     1,749,664  
Allowance for doubtful accounts 3,724 (26,724) (26,724)  
Reserve for inventory   185,938 185,938 58,773
Loss on extinguishment of debt 2,227,437      
(Gain) loss on settlement of debt   478,262 478,262 (105,684)
Loss on settlement of debt and beneficial conversion granted   1,058,262    
Loss on settlements from litigation       82,000
Adjustment to conversion price to induce conversion to equity 258,328      
Beneficial conversion features granted     606,400  
Change in fair value of derivative instruments (1,439,082) (932,624) (1,709,029) 13,600
Change in fair value of derivative instruments     (1,709,029) 23,575
Derivative liabilities related to convertible notes   1,723,269    
Incremental derivative liabilities 958,065   1,796,622  
Stock based compensation 2,583,209 1,095,814 1,287,618 542,600
Contingent compensation payable 15,886 25,000 33,333 10,186
Changes in operating assets and liabilities:        
Accounts receivable (80,248) (8,188)    
Accounts receivable and deferred revenue     7,187 135,507
Inventory and inventory deposit (39,190) 103,287 100,491 151,366
Deferred compensation       329,974
Prepaid expenses and other assets 12,950 (20,477) (5,868) 10,525
Accounts payable and accrued expenses 383,790 281,054 545,625 (215,895)
Accrued interest payable 501,253 230,757 367,694 85,334
Deferred revenue (21,550)      
Net cash used in operating activities (1,015,288) (653,737) (896,346) (948,388)
Cash flow used in investing activities:        
Purchase of fixed assets (16,040) (12,132) (16,414) (4,517)
Net cash used in investing activities (16,040) (12,132) (16,414) (4,517)
Cash flow from financing activities:        
Proceeds from promissory notes payable 805,000   152,000  
Payments on promissory notes payable (75,000) (88,743) (142,873) (83,871)
Proceeds from related party advances and notes payable   6,000 6,000 5,000
Payment on related party notes payable   (5,000) (11,000) (36,000)
Proceeds from convertible promissory notes 135,000 670,000 790,000  
Obligation to issue common stock 15,000 (5,000) (5,000) 5,000
Proceeds from exercise of warrants 22      
Proceeds from issuance of common stock     128,200 1,066,000
Proceeds from issuance of common stock and warrants 155,000 78,200    
Net cash provided by financing activities 1,035,022 655,457 917,327 956,129
Net increase (decrease) in cash 3,694 (10,412) 4,567 3,224
Cash and cash equivalents at beginning of period 15,924 11,357 11,357 8,133
Cash and cash equivalents at end of period 19,618 945 15,924 11,357
Supplemental disclosures:        
Cash paid for interest 50,156 3,196 9,771 6,566
Cash paid for income taxes            
Non-cash financing activities:        
Conversion of debt and interest to other current liability       350,000
Conversion of convertible debentures to common stock 338,500 125,000 225,000  
Captilization of accrued interest into new debt 114,900      
Common stock and warrants issued as debt discount 150,327      
Deemed dividend from Series B Preferred Stock       985,000
Cancellation of shares upon issuance of convertible notes   (200,000) (200,000)  
Cancellation of warrants
        
Non-cash financing activities:        
Stock issued   68,000 68,000  
Accrued interest
        
Non-cash financing activities:        
Stock issued 173,721 8,550 8,550  
Deferred financing fees
        
Non-cash financing activities:        
Stock issued 117,589      
Trade payables
        
Non-cash financing activities:        
Stock issued 259,800      
Settlement of Debt obligation
        
Non-cash financing activities:        
Stock issued       432,750
Patent
        
Non-cash financing activities:        
Stock issued       1,875,000
Contingent note assumed for patent purchased, net of discount       777,272
Warrants issued for release of collateral | Cancellation of warrants
        
Adjustments to reconcile net loss to net cash used in operating activities:        
Issuance of Stock and Warrants for Services or Claims 27,000     286,444
Extensions of Debt | Common Stock
        
Adjustments to reconcile net loss to net cash used in operating activities:        
Issuance of Stock and Warrants for Services or Claims $ 357,320   $ 45,000